A Single-centre, Open-label, Three-period Study of the Pharmacokinetic Effect of PA21 on Warfarin in Healthy Male and Female Adults.
Latest Information Update: 12 May 2021
Price :
$35 *
At a glance
- Drugs Sucroferric oxyhydroxide (Primary) ; Warfarin
- Indications Hyperphosphataemia; Thrombosis
- Focus Pharmacokinetics
- Sponsors Vifor Pharma
- 15 Feb 2012 Actual end date (February 2012) added as reported by ClinicalTrials.gov.
- 15 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 17 Jan 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.